Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE GENERICS NEWS IN BRIEF
September 10, 2007
-
ARCHIVE Leiden Bio Science Park Is Ideal Gateway to Europe: F. van As of Leiden City
September 10, 2007
-
ARCHIVE Reimbursement Begins for 4 Lab Tests
September 10, 2007
-
ARCHIVE Korosho Asks Makers to Present Criteria for Allowances ASAP after Notification of New NHI Prices
September 10, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
September 10, 2007
-
ARCHIVE Toho Pharm. to Expand Business through Alliances
September 10, 2007
-
ARCHIVE National Medical Expenditures Up 3.2% to \33,128.9 Bil.
September 10, 2007
-
ARCHIVE Importance of Life Cycle Management Stressed at TII Seminar
September 10, 2007
-
ARCHIVE NHO to Use Fewer Psychoneurotics, Respiratory Drugs
September 10, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
September 10, 2007
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 10, 2007
-
ARCHIVE Zeria Licenses TM-411 from TMRC
September 10, 2007
-
ARCHIVE SURVEY/Many Patients Still Want Hospital-Based Doctors to Serve as Attending Physicians
September 10, 2007
-
ARCHIVE Takeda Begins PII Trial for TAK-536 for Hypertension
September 10, 2007
-
ARCHIVE TOPICS/Pharma Delegates Launches 2007/2008 Season
September 10, 2007
-
ARCHIVE Korosho to Conduct Studies to Introduce CU System
September 3, 2007
-
ARCHIVE Asian Regulatory Conference to Focus on Multinational Trials, GRP
September 3, 2007
-
ARCHIVE Korosho Approves 35 New Drugs, New Indications
September 3, 2007
-
ARCHIVE Industry's Drug Pricing System Reform Proposals Incompatible with Current System: Mr Tsushima
September 3, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
September 3, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…